Psychotropic therapies

The Premenstrual Syndromes: PMS and PMDD

Volumn , Issue , 2007, Pages 131-140

  Steiner, Meir ^a,b,c,d   Soares, Claudio N ^a,d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057692506     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (66)

1. Eriksson E, Lisjo P, Sundblad C et al. Effect of clomipramine on premenstrual syndrome. Acta Psychiatr Scand 1990; 81:87-8.
2. Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992; 85:39-47.
3. Menkes DB, Taghavi E, Mason PA, Spears GF, Howard RC. Fluoxetine treatment of severe premenstrual syndrome. BMJ 1992; 305:346-7.
4. Hunter MS, Ussher JM, Browne SJ et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23:193-9.
5. Freeman EW, Rickels K, Sondheimer SJ. Fluvoxamine for premenstrual dysphoric disorder: a pilot study J Clin Psychiatry 1996; 57(Suppl 8):56-9.
6. Yonkers KA, Guillion CA, Williams A, Novak K, Rush AJ. Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol 1996; 16:3-8.
7. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1991; 52:290-3.
8. Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS. Treatment of premenstrual syndrome with fluoxetine: a doubleblind, placebo-controlled, crossover study. Obstet Gynecol 1992; 80:339-44.
9. Steiner M, Steinberg S, Stewart D et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995; 332:1529-34.
10. Su TP, Schmidt PJ, Danaceau MA et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997; 16:346-56.
11. Pearlstein T, Stone AB, Lund SA et al. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997; 17:261-6.
12. Ozeren S, Corrakci A, Yucesoy I, Mercan R, Erhan G. Fluoxetine in the treatment of premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol 1997; 73:167-70.
13. Diegoli MS, da Fonseca AM, Diegoli CA, Pinotti JA. A doubleblind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet 1998; 62:63-7.
14. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2003; 18:191-5.
15. Veeninga AT, Westenberg GM, Weusten JT. Fluvoxamine in the treatment of menstrually related mood disorders. Psychopharmacology 1990; 102:414-16.
16. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12:167-76.
17. Cohen LS, Soares CN, Yonkers KA et al. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med 2004; 66:707-13.
18. Pearlstein TB, Bellew KM, Endicott J, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial. Prim Care Companion J Clin Psychiatry 2005; 7:53-60.
19. Yonkers KA, Halbreich U, Freeman E et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA 1997; 278:983-8.
20. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder. A randomized controlled trial. Arch Gen Psychiatry 1999; 56:932-9.
21. Freeman EW, Rickels K, Yonkers KA et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98:737-44.
22. Hsiao M-C, Liu C-Y. Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine. Psychiatry Clin Neurosci 2003; 57:317-21.
23. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1993; 9:133-45.
24. Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry 2005; 66:769-73.
25. Kodesh A, Katz S, Lerner AG, Finkel B, Sigal M. Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder. J Psychopharmacol 2001; 15:58-60.
26. Yonkers KA, Holthausen GA, Poschman K, Howell HB. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol 2006; 26:198-202.
27. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24:417-33.
28. Cohen LS, Miner C, Brown EW et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002; 100:435-44.
29. Landen M, Eriksson O, Sundblad C et al. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl) 2001; 155:292-8.
30. Steiner M, Ravindran A, LeMelledo JM et al. Luteal-phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo controlled trial in Canadian women. Can J Psychiatry 2006: (in press).
31. Steiner M, Hirschberg AL, Bergeron R et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005; 193:352-60.
32. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58:399-402.
33. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998; 59:76-80.
34. Jermain DM, Preece CK, Sykes RL, Kuehi TJ, Sulak PJ. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999; 8:328-32.
35. Halbreich U, Bergeron R, Yonkers KA et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002; 100:1219-29.
36. Kornstein SG, Pearlstein TB, Fayyad R, Farfel GM, Gillespie JA. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry 2006; 67:1624-32.
37. Steinberg S, Annable L, Young SN, Liyanage N. A placebocontrolled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry 1999; 45:313-20.
38. Cohen LS, Soares CN, Lyster A et al. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 2004; 24:540-3.
39. Wikander I, Sundblad C, Andersch B et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18:390-8.
40. Freeman EW, Rickels K, Arredondo F et al. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999; 19:3-8.
41. Freeman EW, Jabara S, Sondheimer SJ, Auletto R. Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. J Womens Health Gend Based Med 2002; 11:459-64.
42. Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 2004; 161:343-51.
43. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997; 33:771-4.
44. Landen M, Nissbrandt H, Allgulander C et al. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007; 32:153-61.
45. Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs 2002; 62:1869-85.
46. Yamada K, Kanba S. Effectiveness of milnacipran for SSRIintolerant patients with premenstrual dysphoric disorder. J Clin Psychopharmacol 2005; 25:398-9.
47. Rapkin A. A review of treatment of premenstrual syndrome & premenstrual dysphoric disorder. Psychoneuroendocrinology 2003; 28:39-53.
48. Wyatt KM, Dimmock PW, O’Brien PMS. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2002; (4):CD001396.
49. Steiner M, Pearlstein T, Cohen LS et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 2006; 15:57-69.
50. Steiner M, Romano SJ, Babcock S et al. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BJOG 2001; 108:462-8.
51. Pearlstein TB, Halbreich U, Batzar ED et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000; 61:101-9.
52. Steiner M, Brown E, Trzepacz P et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Womens Ment Health 2003; 6:71-7.
53. Macdougall M, Steiner M. Treatment of premenstrual dysphoria with selective serotonin re-uptake inhibitors: focus on safety. Expert Opin Drug Saf 2003; 2:1-6.
54. Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord 2005; 85:317-21.
55. Koke SC, Brown EB, Miner CM. Safety and efficacy of fluoxetine in patients who recieve oral contraceptive therapy. Am J Obstet Gynecol 2002; 187:551-5.
56. Steiner M, Lamont J, Steinberg S et al. Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria. Obstet Gynecol 1997; 90:590-5.
57. Pearlstein T, Joliat MJ, Brown EB, Miner CM. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment. Am J Obstet Gynecol 2003; 188:887-95.
58. Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994; 55:332-5.
59. Rapkin AJ, Mikacich JA. Premenstrual syndrome in adolescents:diagnosis and treatment Pediatr Endocrinol Rev 2006; 3(Suppl 1):132-7.
60. Dennersteinl, Morse C, Burrows G, Brown J, Smith M. Alprazolam in the treatment of premenstrual syndrome. In: Dennerstein L, Fraser I, eds. Hormones and Behavior. New York:Elsevier Science Publishing; 1986:175-82.
61. Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987; 70:37-43.
62. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. Arch Gen Psychiatry 1990; 47:270-5.
63. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993; 50:467-73.
64. Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a doubleblind, placebo-controlled crossover study. Obstet Gynecol 1994; 84:379-85.
65. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A doubleblind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995; 274:51-7.
66. Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet 1989; 1:777.